Trial Profile

Imatinib Response in Patients With Chronic Myeloid Leukemia in Function of Abl Polymorphisms

Status: Not yet recruiting

Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imatinib (Primary)
Indications Chronic myeloid leukaemia
Focus Pharmacodynamics; Pharmacogenomic

Most Recent Events

01 Feb 2017 Biomarkers information updated
26 Jul 2013 Planned end date changed from 1 Sep 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov.
26 Jul 2013 Planned initiation date changed from 1 Sep 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com